Enso Ventures

Cognitive Geology Ltd, established in 2014 and based in Edinburgh, UK, specializes in developing advanced geological modeling software for the oil and gas industry. The company's innovative tools help geologists systematically analyze and mitigate the impacts of various geological processes, aiding in the discovery, appraisal, and development of both conventional and unconventional reserves, both onshore and offshore.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs associated with X-linked adrenoleukodystrophy (X-ALD). Neurovia's primary objective is to provide a treatment that can halt the progression of neurological deficits caused by this rare genetic disease. The company has developed a selective thyromimetic agent aimed at improving the quality of life for patients suffering from X-ALD.

UltraSoC Technologies Ltd., established in 2005 and headquartered in Cambridge, UK, specializes in semiconductor intellectual property (IP) for system monitoring, analysis, and optimization. The company's core offering is an independent, non-intrusive system-level architecture that enables real-time, wire-speed monitoring of System-on-Chip (SoC) internal behavior. This IP accelerates and de-risks SoC development by providing engineers with insights into complex interactions between on-chip sub-systems, buses, and software. UltraSoC's toolkit comprises configurable IP modules and software for design-time and run-time configuration, debug, and analytics. Its modules are employed in SoC debug, analytics, optimization, and security applications. As of 2020, UltraSoC operates as a subsidiary of Siemens Aktiengesellschaft.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies for neurological and rare genetic diseases by modulating T-type calcium channels (Cav3). The company’s lead product, CX-8998, targets these channels in the nervous system, and Cavion aims to deliver innovative non-opioid treatments for conditions such as neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, Cavion was previously known as Tau Therapeutics LLC until its name change in 2014. The company is notable for being the first to target Cav3 ion channels in the treatment of solid tumors, with ongoing Phase 1 clinical trials investigating its potential in brain cancer. Cavion's approach leverages advanced chemistry and clinical expertise to enhance the efficacy of existing therapies, such as chemotherapy and radiation, against solid tumor cancers. As of August 2019, Cavion operates as a subsidiary of Jazz Pharmaceuticals plc.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapeutics aimed at enhancing the effectiveness of radiotherapy for cancer patients. The company's lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer. Additionally, GC4419 is being evaluated in Phase IIa trials for the treatment of radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing another candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. The company's research is focused on targeting oxygen metabolic pathways to improve patient outcomes in radiation therapy, and GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Axcella Health Inc., established in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions targeting various biological pathways. The company's pipeline includes AXA1665 for hepatic encephalopathy, AXA1125 and AXA1957 for non-alcoholic steatohepatitis, AXA2678 for muscle atrophy, and AXA4010 for multiple biological pathways.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

SRJ Technologies Group is an engineering company based in Jersey that specializes in the development and distribution of weld-free coupling and leak containment solutions for pipeline and process pipework systems. Founded in 2011 and headquartered in St Helier, the company offers a variety of innovative products, including mechanical couplings, repair clamps, and bespoke enclosure repair units, catering to industries such as oil and gas, desalination, mining, utilities, shipping, and power generation. SRJ Technologies Group's expertise is supported by a UK-based research and development team with over fifty years of experience in fittings manufacture. The company holds an exclusive license for the Snap Ring Joint, a revolutionary pipeline coupling system, and has achieved Type Approval for hydrocarbons service from Lloyds Register and ABS. In addition to its product offerings, SRJ provides Asset Integrity Management consulting services to assist asset owners in developing effective integrity strategies.

Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cancer treatment. The company's lead candidate, CLR 131, is a phospholipid drug conjugate (PDC) currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and other B-cell malignancies. Additionally, Cellectar is developing CLR 1900, a PDC aimed at targeting solid tumors. The company employs a proprietary PDC delivery platform, which combines lipid-like molecules with radioisotopes to enhance the targeting of malignant cells while minimizing effects on healthy tissue. Cellectar has established collaborative programs with various organizations to advance the development of multiple PDCs, further expanding its portfolio. Founded in 2002 and originally named Novelos Therapeutics, Cellectar Biosciences is headquartered in Florham Park, New Jersey.

Cambridge Nanotherm Limited specializes in the development and commercialization of nano-ceramic technology tailored for the electronics industry. Founded in 2010 and based in Haverhill, United Kingdom, the company offers innovative solutions such as the NANOTHERM metal-backed printed circuit board, which features a nano-ceramic dielectric layer applied directly onto aluminum substrates. This technology enhances thermal conductivity and dielectric strength, making it particularly suitable for electronic applications. Additionally, Cambridge Nanotherm produces a chip-on-heat sink design specifically for LED light engines, contributing to effective thermal management in LED lighting modules and other electronic devices.

Carbodeon specializes in the development of super-property nanomaterials, particularly focusing on enhancing the surface properties of composite materials. The company's product offerings include nanodiamond particles, marketed under the name uDiamond, which are designed for applications such as metal plating, durable low-friction coatings, and thermal and mechanical enhancements in polymers. These nanodiamonds are engineered to provide exceptional toughness and performance, making them suitable for demanding industrial applications. Additionally, Carbodeon produces Nicanite, a form of graphitic carbon nitride that can be transformed into carbon nitride film coatings, offering unique properties for various uses. Through these innovative materials, Carbodeon aims to improve the longevity and performance of components in industrial manufacturing and appliances.